#USA #San Antonio #SABCS #Actinium #ATNM-400

Actinium Pharmaceuticals to Present ATNM-400 Efficacy

Actinium Pharmaceuticals, Inc., famed for its innovative targeted radiotherapies, has announced a significant milestone. An abstract showcasing the preclinical efficacy of their investigational therapy, ATNM-400, has been accepted for presentation at the prestigious San Antonio Breast Cancer Symposium (SABCS) 2026, which takes place from December 8–11 in San Antonio, Texas. This development is particularly exciting as the focus is on therapy-resistant breast cancer models, a crucial area in oncology where treatment options are often limited.

The ATNM-400 therapy is a pioneering antibody radioconjugate that uses Actinium-225 (²²⁵Ac) to target HER3, an antigen recognized for its role in tumor biology and resistance to treatment in various solid tumors, including breast cancer. This unique approach combines the specificity of monoclonal antibodies with potent alpha-particle radiation, delivering a targeted cytotoxic payload directly to tumors.

The upcoming poster presentation will delve into how ATNM-400 demonstrates efficacy across different subtypes of therapy-resistant breast cancer. This reinforces previous findings related to its activity in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and ovarian cancer. Such results affirm the crucial role of ATNM-400 as a potential pan-tumor therapy, guiding further investigations into its application as both a standalone treatment and in combination with existing cancer therapies.

Sandesh Seth, Chairman and CEO of Actinium Pharmaceuticals, expressed his enthusiasm for the presentation, emphasizing the company's vision to develop ATNM-400 as a transformative treatment option across multiple oncology settings. “These findings highlight the substantial possibility of ATNM-400 extending its benefits beyond a single type of cancer, addressing the urgent need for effective therapies in patients facing treatment-resistant tumors,” Seth stated.

Understanding ATNM-400 and Its Mechanism

ATNM-400 employs a theranostic approach through its design, which not only targets HER3 with precision but also allows for real-time monitoring of the drug’s distribution via non-invasive imaging techniques. This capability is based on the behavior of the HER3-targeting monoclonal antibody, barecetamab, paired with the alpha-emitting isotope Actinium-225, which possesses a favorable half-life for therapeutic applications.

Importantly, HER3 is implicated in contributing to resistance against standard cancer therapies, making ATNM-400 distinct from other therapies. While other radiotherapy approaches, such as those targeting PSMA, exist, they do not address the broader implications of HER3 in various cancers. This differentiation establishes ATNM-400 as a versatile option that can potentially manage cancers that do not express PSMA, further expanding the patient population that can benefit from targeted radiotherapies.

ATNM-400’s development is supported by compelling preclinical data showing its potential in several cancer types. To date, its efficacy has been validated not only in breast but also in prostate, non-small cell lung, and colorectal cancers. These preclinical findings underscore the ongoing commitment of Actinium Pharmaceuticals to pursue innovative therapies that could reshape management strategies in oncology.

Future Prospects

As Actinium advances into its first human clinical trials for prostate cancer and continues its development across other solid tumors, the excitement surrounding ATNM-400 grows. The upcoming SABCS 2026 presentation is set to provide more detailed insights into these promising results, fostering collaboration and interest among the oncology community. Actinium's dedication to addressing treatment-resistant cancers positions it as a frontrunner in cancer therapy, potentially changing the standard of care for patients battling this formidable disease.

In summary, the acceptance of the abstract for ATNM-400 at SABCS 2026 marks a pivotal moment for Actinium Pharmaceuticals. With its unique approach and promising preclinical results, ATNM-400 could signify a leap forward in developing targeted radiotherapeutic options that face the challenge of treatment resistance head-on.